Definitions
from The American Heritage® Dictionary of the English Language, 5th Edition.
- noun A humanized monoclonal antibody, used as an intravenous drug to treat severe asthma.
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
monoclonal antibody used mainly inallergy -relatedasthma therapy with the purpose of reducing allergichypersensitivity .
Etymologies
from The American Heritage® Dictionary of the English Language, 4th Edition
Support
Help support Wordnik (and make this page ad-free) by adopting the word omalizumab.
Examples
-
The drug called omalizumab, marketed as Xolair, is given as a monthly injection by a doctor and has been shown to reduce the number of times a child has a severe attack.
Telegraph.co.uk - Telegraph online, Daily Telegraph and Sunday Telegraph 2010
-
A new drug called "omalizumab" (sounds like something Aleister Crowley would utter while trying to breathe life into a homunculus) promises to stop allergic reactions by blocking the action of the antibodies that trigger the reaction.
Boing Boing: December 16, 2001 - December 22, 2001 Archives 2001
-
Researchers at Stanford University and Children's Hospital Boston created a new, expedited approach in which children were exposed to small amounts of milk powder along with the allergy drug omalizumab.
The Seattle Times 2011
-
In the study, 11 children with milk allergies were given omalizumab for nine weeks before being given a dose of two grams of milk protein, Nadeau said.
The Seattle Times 2011
-
It is estimated that just over 300 of these children may be eligible for treatment with omalizumab [10].
-
More recently omalizumab was approved by the same regulator as add-on therapy for severe persistent allergic asthma in children aged 6 to 11 years [3].
-
Last month the Scottish Medicines Consortium (SMC) accepted the use of omalizumab for children in Scotland aged 6 to 11 years with severe, persistent allergic asthma who are prescribed chronic systemic steroids [6].
-
Results from a pivotal study submitted to NICE showed that omalizumab reduced asthma attacks by a third after 24 weeks of treatment [2] and provided an overall reduction of 50% at one year [2].
-
(NICE) has decided against recommending omalizumab for children aged 6 to 11 years with severe, persistent allergic asthma in England and Wales because it does not consider it to be
-
By targeting IgE, omalizumab can prevent the onset of debilitating symptoms, such as shortness of breath and wheezing, in severely affected patients.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.